Bharat Biotech International Ltd. may launch an IPO to raise ₹4,000–5,000 crore, monitoring market conditions. Founded in Hyderabad, it has delivered over 9 billion vaccine doses globally.
Indian vaccine developer Bharat Biotech International Ltd. is considering an initial public offering (IPO) that could raise around ₹4,000–5,000 crore, according to sources cited by CNBC-TV18.
The company is reportedly watching the market situation before approaching SEBI and has not finalised the timing of the potential share sale.
Founded in 1996, the Hyderabad-based company says it has delivered more than 9 billion vaccine doses globally. Its portfolio includes vaccines for Covid-19 and hepatitis B, as well as treatments for burns and diarrhoea.
India’s market for first-time share sales has seen a subdued start to 2026 following two consecutive years of record fund-raising. Equities have come under pressure amid slowing earnings growth, global trade uncertainty, and uneven foreign inflows. Large offerings in the pipeline include those of Jio Platforms Ltd., National Stock Exchange of India Ltd., and several property firms.
Also read: India to offer free HPV vaccine to 14-Year-old girls in nationwide campaign
(Edited by : Ajay Vaishnav)
First Published: Feb 27, 2026 5:40 PM IS
